Download PDF
Semin Respir Crit Care Med 2016; 37(04): 640-646
DOI: 10.1055/s-0036-1584803
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antivirals for Respiratory Viral Infections: Problems and Prospects

Qiang Liu   *
1   The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China
,
Yuan-hong Zhou   *
1   The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China
,
Feng Ye   *
1   The First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, China
,
Zhan-qiu Yang
2   State Key Laboratory of Virology, Institute of Medical Virology, School of Medicine, Wuhan University, Wuhan, China
› Author Affiliations
Further Information

Publication History

Publication Date:
03 August 2016 (online)

   Permissions and Reprints

Abstract

In the past two decades, several newly emerging and reemerging viral respiratory pathogens including several influenza viruses (avian influenza and pandemic influenza), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV), have continued to challenge medical and public health systems. Thereafter, the development of cost-effective, broad-spectrum antiviral agents is the urgent mission of both virologists and pharmacologists. Current antiviral developments have focused targets on viral entry, replication, release, and intercellular pathways essential for viral life cycle. Here, we review the current literature on challenges and prospects in the development of these antivirals.

Keywords

respiratory virus - antiviral - entry - replication - pathway

* All three authors contributed equally to this work.


 

  • References

  • 1 Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med 2012; 18 (3) 271-278
    CrossrefPubMedGoogle Scholar
  • 2 Liu Q, Liu DY, Yang ZQ. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin 2013; 34 (10) 1257-1269
    CrossrefPubMedGoogle Scholar
  • 3 Hirst M, Astell CR, Griffith M , et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 2004; 10 (12) 2192-2195
    CrossrefPubMedGoogle Scholar
  • 4 Peiris M, Yam WC, Chan KH, Ghose P, Shortridge KF. Influenza A H9N2: aspects of laboratory diagnosis. J Clin Microbiol 1999; 37 (10) 3426-3427
    PubMedGoogle Scholar
  • 5 Peiris M, Yuen KY, Leung CW , et al. Human infection with influenza H9N2. Lancet 1999; 354 (9182) 916-917
    CrossrefPubMedGoogle Scholar
  • 6 Su S, Bi Y, Wong G, Gray GC, Gao GF, Li S. Epidemiology, evolution and recent outbreaks of avian influenza viruses in China: A Review. J Virol 2015; 89 (17) 8671-8676
    CrossrefPubMedGoogle Scholar
  • 7 Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2015; 89 (17) 8671-8676
    PubMedGoogle Scholar
  • 8 Osterhaus AD. New respiratory viruses of humans. Pediatr Infect Dis J 2008; 27 (10, Suppl): S71-S74
    CrossrefPubMedGoogle Scholar
  • 9 Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe 2015; 17 (3) 295-300
    CrossrefPubMedGoogle Scholar
  • 10 Knipe DM, Howley PM. Fields virology. 6th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2013
    Google Scholar
  • 11 Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci 2014; 1323: 115-139
    CrossrefPubMedGoogle Scholar
  • 12 Simões EA, DeVincenzo JP, Boeckh M , et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015; 211 (Suppl. 01) S1-S20
    CrossrefPubMedGoogle Scholar
  • 13 Zhu JD, Meng W, Wang XJ, Wang HC. Broad-spectrum antiviral agents. Front Microbiol 2015; 6: 517
    PubMedGoogle Scholar
  • 14 Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001; 358 (9291) 1410-1416
    CrossrefPubMedGoogle Scholar
  • 15 Henrickson KJ. Advances in the laboratory diagnosis of viral respiratory disease. Pediatr Infect Dis J 2004; 23 (1, Suppl) S6-S10
    CrossrefPubMedGoogle Scholar
  • 16 Principi N, Esposito S. Antigen-based assays for the identification of influenza virus and respiratory syncytial virus: why and how to use them in pediatric practice. Clin Lab Med 2009; 29 (4) 649-660
    CrossrefPubMedGoogle Scholar
  • 17 Pérez-Ruiz M, Pedrosa-Corral I, Sanbonmatsu-Gámez S, Navarro-Marí M. Laboratory detection of respiratory viruses by automated techniques. Open Virol J 2012; 6: 151-159
    PubMedGoogle Scholar
  • 18 Dundas NE, Ziadie MS, Revell PA , et al. A lean laboratory: operational simplicity and cost effectiveness of the Luminex xTAG™ respiratory viral panel. J Mol Diagn 2011; 13 (2) 175-179
    CrossrefPubMedGoogle Scholar
  • 19 Edinger TO, Pohl MO, Stertz S. Entry of influenza A virus: host factors and antiviral targets. J Gen Virol 2014; 95 (Pt 2): 263-277
    CrossrefPubMedGoogle Scholar
  • 20 Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 2010; 201 (7) 1007-1015
    CrossrefPubMedGoogle Scholar
  • 21 Nicholls JM, Moss RB, Haslam SM. The use of sialidase therapy for respiratory viral infections. Antiviral Res 2013; 98 (3) 401-409
    CrossrefPubMedGoogle Scholar
  • 22 Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206 (12) 1844-1851
    CrossrefPubMedGoogle Scholar
  • 23 Huentelman MJ, Zubcevic J, Hernández Prada JA , et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 2004; 44 (6) 903-906
    CrossrefPubMedGoogle Scholar
  • 24 Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006; 98 (4) 463-471
    CrossrefPubMedGoogle Scholar
  • 25 Friesen RH, Koudstaal W, Koldijk MH , et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE 2010; 5 (2) e9106
    CrossrefPubMedGoogle Scholar
  • 26 Lagos R, DeVincenzo JP, Muñoz A , et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009; 28 (9) 835-837
    CrossrefPubMedGoogle Scholar
  • 27 Han YM, Seo HJ, Choi SH , et al. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia. J Korean Med Sci 2015; 30 (7) 924-931
    CrossrefPubMedGoogle Scholar
  • 28 Ramilo O, Lagos R, Sáez-Llorens X , et al; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014; 33 (7) 703-709
    CrossrefPubMedGoogle Scholar
  • 29 Hegele RG. Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner?. Eur Respir J 2011; 38 (2) 246-247
    CrossrefPubMedGoogle Scholar
  • 30 Plemper RK. Cell entry of enveloped viruses. Curr Opin Virol 2011; 1 (2) 92-100
    CrossrefPubMedGoogle Scholar
  • 31 Cosset FL, Lavillette D. Cell entry of enveloped viruses. Adv Genet 2011; 73: 121-183
    PubMedGoogle Scholar
  • 32 Teissier E, Penin F, Pécheur EI. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 2011; 16 (1) 221-250
    PubMedGoogle Scholar
  • 33 de Vries E, Tscherne DM, Wienholts MJ , et al. Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog 2011; 7 (3) e1001329
    CrossrefPubMedGoogle Scholar
  • 34 Sun X, Whittaker GR. Role of the actin cytoskeleton during influenza virus internalization into polarized epithelial cells. Cell Microbiol 2007; 9 (7) 1672-1682
    CrossrefPubMedGoogle Scholar
  • 35 Ehrhardt C, Marjuki H, Wolff T , et al. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol 2006; 8 (8) 1336-1348
    CrossrefPubMedGoogle Scholar
  • 36 Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog 2010; 6 (9) e1001099
    CrossrefPubMedGoogle Scholar
  • 37 Li S, Sieben C, Ludwig K , et al. pH-Controlled two-step uncoating of influenza virus. Biophys J 2014; 106 (7) 1447-1456
    CrossrefPubMedGoogle Scholar
  • 38 Garcia NK, Guttman M, Ebner JL, Lee KK. Dynamic changes during acid-induced activation of influenza hemagglutinin. Structure 2015; 23 (4) 665-676
    CrossrefPubMedGoogle Scholar
  • 39 Ochiai H, Sakai S, Hirabayashi T, Shimizu Y, Terasawa K. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res 1995; 27 (4) 425-430
    CrossrefPubMedGoogle Scholar
  • 40 Chen HW, Cheng JX, Liu MT , et al. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res 2013; 99 (3) 371-382
    CrossrefPubMedGoogle Scholar
  • 41 Müller KH, Kainov DE, El Bakkouri K , et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br J Pharmacol 2011; 164 (2) 344-357
    CrossrefPubMedGoogle Scholar
  • 42 Vigant F, Lee J, Hollmann A , et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 2013; 9 (4) e1003297
    CrossrefPubMedGoogle Scholar
  • 43 Wolf MC, Freiberg AN, Zhang T , et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010; 107 (7) 3157-3162
    CrossrefPubMedGoogle Scholar
  • 44 Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009; 81 (2) 132-140
    CrossrefPubMedGoogle Scholar
  • 45 Boriskin YS, Leneva IA, Pécheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15 (10) 997-1005
    CrossrefPubMedGoogle Scholar
  • 46 Burtseva EI, Shevchenko ES, Beliakova NV , et al. [Monitoring of the sensitivity of epidemic influenza virus strains isolated in Russia to etiotropic chemical agents]. Vopr Virusol 2009; 54 (5) 24-28
    PubMedGoogle Scholar
  • 47 DeVincenzo JP, Whitley RJ, Mackman RL , et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371 (8) 711-722
    CrossrefPubMedGoogle Scholar
  • 48 Douglas JL, Panis ML, Ho E , et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 2005; 49 (6) 2460-2466
    CrossrefPubMedGoogle Scholar
  • 49 Elshabrawy HA, Fan J, Haddad CS , et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J Virol 2014; 88 (8) 4353-4365
    CrossrefPubMedGoogle Scholar
  • 50 Gu R, Liu LA, Wei D. Drug inhibition and proton conduction mechanisms of the influenza a M2 proton channel. Adv Exp Med Biol 2015; 827: 205-226
    PubMedGoogle Scholar
  • 51 Wei C, Pohorille A. M2 proton channel: toward a model of a primitive proton pump. Orig Life Evol Biosph 2015; 45 (1–2) 241-248
    CrossrefPubMedGoogle Scholar
  • 52 Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 2005; 341 (1) 102-106
    CrossrefPubMedGoogle Scholar
  • 53 Huang Y, Hu B, Wen X , et al. Evolution analysis of the matrix (M) protein genes of 17 H9N2 chicken influenza viruses isolated in northern China during 1998-2008. Virus Genes 2009; 38 (3) 398-403
    CrossrefPubMedGoogle Scholar
  • 54 Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58 (16) 433-435
    PubMedGoogle Scholar
  • 55 Wang J, Ma C, Wang J , et al. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem 2013; 56 (7) 2804-2812
    CrossrefPubMedGoogle Scholar
  • 56 Rodriguez-Frandsen A, Alfonso R, Nieto A. Influenza virus polymerase: Functions on host range, inhibition of cellular response to infection and pathogenicity. Virus Res 2015; 209: 23-38
    CrossrefPubMedGoogle Scholar
  • 57 Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100 (2) 446-454
    CrossrefPubMedGoogle Scholar
  • 58 Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep 2015; 9 (1) 79-81
    CrossrefPubMedGoogle Scholar
  • 59 Kiso M, Takahashi K, Sakai-Tagawa Y , et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 2010; 107 (2) 882-887
    CrossrefPubMedGoogle Scholar
  • 60 Yamada K, Koyama H, Hagiwara K , et al. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. Microbes Infect 2012; 14 (9) 740-747
    CrossrefPubMedGoogle Scholar
  • 61 Warren TK, Wells J, Panchal RG , et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508 (7496) 402-405
    CrossrefPubMedGoogle Scholar
  • 62 Wang G, Deval J, Hong J , et al. Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 2015; 58 (4) 1862-1878
    CrossrefPubMedGoogle Scholar
  • 63 Krumm SA, Ndungu JM, Yoon JJ , et al. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS ONE 2011; 6 (5) e20069
    CrossrefPubMedGoogle Scholar
  • 64 Brochot E, François C, Castelain S , et al. A new tool to study ribavirin-induced haemolysis. Antivir Ther 2012; 17 (7) 1311-1317
    CrossrefPubMedGoogle Scholar
  • 65 Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005; 68 (1) 10-17
    CrossrefPubMedGoogle Scholar
  • 66 Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008; 52 (11) 3889-3897
    CrossrefPubMedGoogle Scholar
  • 67 Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis 1980; 141 (5) 548-554
    CrossrefPubMedGoogle Scholar
  • 68 Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57 (1) 8-13
    CrossrefPubMedGoogle Scholar
  • 69 Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem 2004; 279 (32) 33035-33038
    CrossrefPubMedGoogle Scholar
  • 70 Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 2011; 108 (14) 5777-5782
    CrossrefPubMedGoogle Scholar
  • 71 Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012; 22 (6) 263-272
    CrossrefPubMedGoogle Scholar
  • 72 Graham AC, Temple RM, Obar JJ. Mast cells and influenza a virus: association with allergic responses and beyond. Front Immunol 2015; 6: 238
    PubMedGoogle Scholar
  • 73 Frieman M, Basu D, Matthews K , et al. Yeast based small molecule screen for inhibitors of SARS-CoV. PLoS ONE 2011; 6 (12) e28479
    CrossrefPubMedGoogle Scholar
  • 74 Adedeji AO, Sarafianos SG. Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol 2014; 8: 45-53
    CrossrefPubMedGoogle Scholar
  • 75 Valiente-Echeverría F, Hermoso MA, Soto-Rifo R. RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity. Rev Med Virol 2015; 25 (5) 286-299
    CrossrefPubMedGoogle Scholar
  • 76 Tanner JA, Zheng BJ, Zhou J , et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 2005; 12 (3) 303-311
    CrossrefPubMedGoogle Scholar
  • 77 Adedeji AO, Singh K, Kassim A , et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 2014; 58 (8) 4894-4898
    CrossrefPubMedGoogle Scholar
  • 78 Liu G, Xiang Y, Guo C, Pei Y, Wang Y, Kitazato K. Cofilin-1 is involved in regulation of actin reorganization during influenza A virus assembly and budding. Biochem Biophys Res Commun 2014; 453 (4) 821-825
    CrossrefPubMedGoogle Scholar
  • 79 Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology 2011; 411 (2) 229-236
    CrossrefPubMedGoogle Scholar
  • 80 Chase GP, Rameix-Welti MA, Zvirbliene A , et al. Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting. PLoS Pathog 2011; 7 (9) e1002187
    CrossrefPubMedGoogle Scholar
  • 81 Perwitasari O, Johnson S, Yan X , et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol 2014; 88 (17) 10228-10243
    CrossrefPubMedGoogle Scholar
  • 82 Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284 (43) 29798-29808
    CrossrefPubMedGoogle Scholar
  • 83 Rossignol JF. Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol 2009; 5 (6) 667-674
    CrossrefPubMedGoogle Scholar
  • 84 de Wilde AH, Li Y, van der Meer Y , et al. Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J Virol 2013; 87 (3) 1454-1464
    CrossrefPubMedGoogle Scholar
  • 85 Hamamoto I, Harazaki K, Inase N, Takaku H, Tashiro M, Yamamoto N. Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle. Jpn J Infect Dis 2013; 66 (4) 276-283
    CrossrefPubMedGoogle Scholar
  • 86 Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg 2014; 55 (4) 109-129
    PubMedGoogle Scholar
  • 87 Varghese JN, Smith PW, Sollis SL , et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6 (6) 735-746
    CrossrefPubMedGoogle Scholar
  • 88 Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53 (1) 186-192
    CrossrefPubMedGoogle Scholar
  • 89 Dharan NJ, Gubareva LV, Meyer JJ , et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301 (10) 1034-1041
    CrossrefPubMedGoogle Scholar
  • 90 Planz O. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res 2013; 98 (3) 457-468
    CrossrefPubMedGoogle Scholar
  • 91 Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009; 64 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 92 Droebner K, Pleschka S, Ludwig S, Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res 2011; 92 (2) 195-203
    CrossrefPubMedGoogle Scholar
  • 93 Mazur I, Wurzer WJ, Ehrhardt C , et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007; 9 (7) 1683-1694
    CrossrefPubMedGoogle Scholar
  • 94 Guidelines for Management of Avian H7N9 Influenza Infection. 2013 http://www.moh.gov.cn/ewebeditor/uploadfile/2013/04/20130410212136993.doc
    PubMedGoogle Scholar
  • 95 Guidelines for Management of Pandemic. (H1N1) 2009 Influenza. 2009 http://www.moh.gov.cn/mohwsyjbgs/s9990/200910/43111.shtml
    PubMedGoogle Scholar
  • 96 Shang X, Pan H, Li M, Miao X, Ding H. Lonicera japonica Thunb.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol 2011; 138 (1) 1-21
    CrossrefPubMedGoogle Scholar
  • 97 WHO monographs on selected medicinal plants. 1999 http://apps.who.int/medicinedocs/en/d/Js2200e/
    PubMedGoogle Scholar
  • 98 Li C, Dai Y, Zhang SX , et al. Quinoid glycosides from Forsythia suspensa. Phytochemistry 2014; 104: 105-113
    CrossrefPubMedGoogle Scholar
  • 99 Xu JJ, Wu X, Li MM , et al. Antiviral activity of polymethoxylated flavones from “Guangchenpi”, the edible and medicinal pericarps of citrus reticulata ‘Chachi’. J Agric Food Chem 2014; 62 (10) 2182-2189
    CrossrefPubMedGoogle Scholar
  • 100 Liu Q, Lu L, Hua M , et al. Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo. J Ethnopharmacol 2013; 150 (2) 521-528
    CrossrefPubMedGoogle Scholar
  • 101 Ling JX, Wei F, Li N , et al. Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea. Acta Pharmacol Sin 2012; 33 (12) 1533-1541
    CrossrefPubMedGoogle Scholar